Publication Name	World Journal of Gastroenterology
Manuscript ID	19423
Country	South Korea

Received	2015-05-08 08:52
Peer-Review Started	2015-05-11 14:14
To Make the First Decision	2015-06-19 17:40
Return for Revision	2015-06-24 14:57
Revised	2015-07-06 21:26
Second Decision	2015-08-19 15:09
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-09-02 15:16
Articles in Press	2015-09-02 15:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-11-03 15:50
Publish the Manuscript Online	2015-12-09 17:57

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection
Manuscript Source	Unsolicited Manuscript
All Author List	Ji Hyun Lim, Dong Ho Lee, Seong Tae Lee, Nayoung Kim, Young Soo Park, Cheol Min Shin and In Sung Song
Funding Agency and Grant Number
Corresponding Author	Dong Ho Lee, MD, Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam, Gyeonggi-do 463-707, South Korea. dhljohn@yahoo.co.kr
Key Words	Helicobacter pylori; Moxifloxacin-based triple; Non-bismuth quadruple; Second-line; Eradication
Core Tip	We aimed to compare 1-wk and 2-wk moxifloxacin-containing triple therapies after non-bismuth quadruple therapy failure for Helicobacter pylori (H. pylori) infection, especially in patients from a region known to be associated with a high resistance to antibiotics. The eradication rate of the 2-wk group was significantly higher than that of the 1-wk group (76.3% vs 56.7%, P < 0.05), and the incidence of side effects was similar. Thus, a 2-wk regimen may be a reasonable choice as second-line therapy for the eradication of H. pylori infection after non-bismuth quadruple therapy failure.
Publish Date	2015-12-09 17:57
Citation	Lim JH, Lee DH, Lee ST, Kim N, Park YS, Shin CM, Song IS. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. World J Gastroenterol 2015; 21(46): 13124-13131
URL	http://www.wjgnet.com/1007-9327/full/v21/i46/13124.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i46.13124

Full Article (PDF)	WJG-21-13124.pdf
Full Article (Word)	WJG-21-13124.doc
Manuscript File	19423-Review.docx
Answering Reviewers	19423-Answering reviewers.pdf
Audio Core Tip	19423-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	19423-Conflict-of-interest statement.pdf
Copyright License Agreement	19423-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	19423-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	19423-Language certificate.pdf
Peer-review Report	19423-Peer-review(s).pdf
Scientific Editor Work List	19423-Scientific editor work list.pdf